![Figure. Melanoma cell line (624) was treated with bortezomib [10 nM] and analyzed for susceptibility to NK cell (left) and gp100-specific CD8+ CTL (middle) - mediated cytotoxicity in a 5h Cr51 cytotoxicity assay. Right - bortezomib-treated and untreated gp100:209 peptide pulsed 624 melanoma cells analyzed for susceptibility to gp100-specific CD8+ CTL-mediated cytotoxicity at a E:T ratio of 4:1](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/11/10.1182_blood.v110.11.1789.1789/2/3002.jpeg?Expires=1748983127&Signature=ASBAeBRA0z-vceqPuBCOzJQuLsBbgJx9Ifa7yBpv2Ee2TQ~G0ZF60zTJnvnDSC-2meJ9NlVstthFtMwobKFU-7LT7R9jrtkOfkRmsxLYcA8A0Q9aWJIvpZdDORuVrzXU7iN6uJrBelZ3Oq93qWLGFLuhf7R505heyOHMpHhTXWuwOfaucLFMPdY1t84h6q0j2F454rCjgw4ufyyZ9jjWuqgVmOjz-2sSua8sXMJ6lFlD4bV4Dhz-JR1dpoZjdS76XGTnKvKOGrpD0QO7WWbhxLYVHk9X53tD6Kqpc5cTkEtXvzRbPAvx5w~V~R5xcKQYzfQWhjjuiXCvH~SHmO4DCQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Figure. Melanoma cell line (624) was treated with bortezomib [10 nM] and analyzed for susceptibility to NK cell (left) and gp100-specific CD8+ CTL (middle) - mediated cytotoxicity in a 5h Cr51 cytotoxicity assay. Right - bortezomib-treated and untreated gp100:209 peptide pulsed 624 melanoma cells analyzed for susceptibility to gp100-specific CD8+ CTL-mediated cytotoxicity at a E:T ratio of 4:1
